000			03983nam a22004335i 4500
001			978-1-4419-6609-4
003			DE-He213
005			20140220084510.0
007			cr nn 008mamaa
008			130531s2010 xxu| s |||| 0|eng d
020			_a9781441966094 _9978-1-4419-6609-4
024	7		_a10.1007/978-1-4419-6609-4 _2doi
050		4	_aRC261-271
072		7	_aMJCL _2bicssc
072		7	_aMED062000 _2bisacsh
082	0	4	_a614.5999 _223
100	1		_aMeyer, Tim. _eeditor.
245	1	0	_aVascular Disruptive Agents for the Treatment of Cancer _h[electronic resource] / _cedited by Tim Meyer.
264		1	_aNew York, NY : _bSpringer New York : _bImprint: Springer, _c2010.
300			_aX, 258p. 32 illus., 21 illus. in color. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_aDevelopment of Vascular Disrupting Agents -- Development of Vascular Disrupting Agents -- Pre-Clinical Development -- The Discovery and Characterisation of Tumour Endothelial Markers -- The Use of Animal Models in the Assessment of Tumour Vascular Disrupting Agents (VDAs) -- Combination Therapy with Chemotherapy and VDAs -- Lessons from Animal Imaging in Preclinical Models -- Combining Antiangiogenic Drugs with Vascular Disrupting Agents Rationale and Mechanisms of Action -- Imaging in the Development of Vascular Disruptive Agents -- MRI to Assess Vascular Disruptive Agents -- Contrast Ultrasound in Imaging Tumor Angiogenesis -- Clinical Development -- The Clinical Development of Tubulin Binding Vascular Disrupting Agents -- ASA404 (DMXAA): New Concepts in Tumour Vascular Targeting Therapy -- Vascular Disruptive Agents in Combination with Radiotherapy.
520			_aTumour survival and growth is critically dependent on an independent blood supply. As such tumour vasculature presents an ideal target for cancer therapy that is widely applicable, accessible and genetically stable rendering it less prone to resistance. Two approaches have been explored for cancer therapy; firstly the prevention of new vessel formation with inhibitors of angiogenesis, and secondly the destruction of existing tumour blood vessels with so called vascular disruptive agents (VDAs). While the first approach appears to delay tumour progression, the second has the potential to cause massive cell death and tumour regression. It is the second approach of vascular targeting that is the focus of this book. Since the tubulin binding agent combretastatin, derived from the bark of the African bush willow, was discovered by George R Pettit to have antimitotic properties over twenty years ago, the field of vascular targeting has expanded steadily. Coincident with the preclinical and clinical development of these agents, there have been advances in our understanding of their mechanism of action and in the technology required to assess their effects. This book aims to provide a comprehensive account of the current state of the art. Preclinical target identification and validation are discussed and the optimum pre-clinical animal models described. The imaging modalities that can be used to assess the efficacy of these agents are examined and a comprehensive review of the clinical development of key drugs is provided. Finally, the recent research exploring rational combinations of VDAs with other agents is reviewed and the potential place of VDAs in the future of cancer therapy is critically appraised.
650		0	_aMedicine.
650		0	_aOncology.
650		0	_aToxicology.
650	1	4	_aBiomedicine.
650	2	4	_aCancer Research.
650	2	4	_aPharmacology/Toxicology.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9781441966087
856	4	0	_uhttp://dx.doi.org/10.1007/978-1-4419-6609-4
912			_aZDB-2-SBL
999			_c110668 _d110668